Health Catalyst, Inc.
HealthcareNASDAQ:HCAT · NASDAQ Global Select
+$0.21 today
Vol 1.37M · Avg 1.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-72.4%
avg -24.7%
ROIC
-8.6%
avg -28.4%
ROA
-35.4%
avg -26.1%
Analysis
ROIC is currently the strongest return metric at -8.6% versus its period average of -28.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Benjamin Albert | Chief Executive Officer & Director | $937,887.00 | — | 53 | $364,539.00 | 0.49% |
Linda Llewelyn | Senior Advisor | $485,113.00 | — | 59 | $321,132.00 | 0.43% |
Benjamin Landry | General Counsel & Secretary of the Board | $419,036.00 | — | 44 | $364,539.00 | 0.49% |
Jason Alger | Chief Financial Officer | $365,366.00 | — | 42 | $722,840.00 | 0.98% |
Kristen Berry | Senior Vice President of Public Relations | — | — | — | — | — |
Jeffrey Selander | Senior Vice President of International | — | — | — | — | — |
Kyle J. Salyers | Chief Strategy Officer & Senior Vice President of Corporate Development | — | — | — | — | — |
Matt Hopper | Senior Vice President of Finance & Head of Investor Relations | — | — | — | — | — |
Amanda Flanders | Senior Vice President of Marketing & Communications | — | — | — | — | — |
Carrie Kozlowski | Chief Marketing Officer | — | — | — | — | — |
Cathy R. Menkiena | Senior VP & GM of Strategic Accounts, North America | — | — | — | — | — |
Holly Rimmasch | Senior Vice President & Chief Clinical Officer | — | — | — | — | — |
Sadiqa Mahmood | GM & Senior VP of Life Sciences Business | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$221,381.51
Net Sentiment
$221,381.51
Net selling
Most Active
Landry Benjamin
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $221,381.51 over the last 12 months. That adds up to net selling of $221,381.51. Landry Benjamin was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +29.0% | +0.3% (7yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +29.0% over three years. Forward estimates point to Revenue at +0.3% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Solana Company
NASDAQ:HSDT
$89.92M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
Who manages HCAT?
Health Catalyst, Inc. (HCAT) lists 13 active executives. The top listed executive is Kristen Berry, Senior Vice President of Public Relations.
Are HCAT insiders buying or selling?
Recent insider activity shows net selling of $4.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.